LIN vs PTCT · P/E 34, rev $33.99B vs rev $806.8M
Linde plc Ordinary Shares (LIN) versus PTC Therapeutics Inc (PTCT) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
PTC Therapeutics Inc (PTCT) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported PTCT revenue for 2024-12-31 was $806.8M. Net income was -$363.3M. Revenue was down 14.0% from 2023-12-31 to 2024-12-31. PTCT currently screens at market cap $6.51B.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. PTCT currently screens at market cap $6.51B.
Not investment advice. Open the LIN and PTCT stock pages for the full models.
Not investment advice.